SYNOPSIS: Sakar Healthcare received EMA approval to manufacture Imatinib tablets for Accord’s EU market, marking its first oncology product for Europe and supporting higher capacity utilisation and revenue growth ahead.
During Friday’s trading session, shares of a company involved in the manufacturing Research & Development (R&D) of Pharmaceutical products surged nearly 3 percent on NSE, after the company became a manufacturing hub for Accord’s EU oncology drug.
At 02:58 p.m., shares of Sakar Healthcare Limited were trading in green at Rs. 423.5 on NSE, up by more than 2.4 percent, compared to its previous closing price of Rs. 412.95, with a market cap of Rs. 495.5 crores.
What’s the News
According to the latest regulatory filings with the NSE, Sakar Healthcare Limited has received approval for its oncology manufacturing facility located on the Bavla-Bagodara Highway in Ahmedabad to manufacture Imatinib Accord 100 mg and 400 mg film-coated tablets for Accord Healthcare (UK), intended for supply to the European Union (EU) market.
With this development, Sakar’s oncology unit has been designated as a manufacturing source for Accord’s European distribution of Imatinib 100 mg and 400 mg tablets. Notably, this product marks the first of nine oncology products planned to be manufactured by Sakar for Accord, positioning the company for deeper participation in the European oncology supply chain.
Management expects the inclusion of Imatinib to support improved capacity utilisation and contribute positively to revenue growth in the coming financial year. Additionally, the approval strengthens Sakar’s overseas footprint, enabling the company to prepare for the supply of nearly a dozen approved products to international markets.
Financials & More
Sakar Healthcare reported a significant growth in its revenue from operations, showing a year-on-year increase of more than 34 percent from Rs. 42.78 crores in Q2 FY25 to Rs. 57.56 crores in Q2 FY26. In contrast, its net profit during the same period decreased from Rs. 4.8 crores to Rs. 4.54 crores, representing a fall of over 5 percent YoY.
Sakar Healthcare Limited is engaged in the business of manufacturing pharmaceutical products. It operates a diversified business model comprising CDMO services, own brand exports and product development technology transfer, enabling a balance between stability and strategic growth.
The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectable (SVP) in ampoules, vials & lyophilised injections, oral solid dosages and research & development of the above products.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
